Skip to content

Mast Cell Activation Test in Allergic Disease

Assessment of Mast Cell Activation Diagnostic Test in Patients With Allergic Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03406325
Enrollment
19
Registered
2018-01-23
Start date
2018-02-01
Completion date
2019-12-01
Last updated
2020-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaphylaxis, Asthma, Chronic Idiopathic Urticaria, Eczema, Food Allergy, Mast Cell Activation Syndrome, Mastocytosis

Keywords

mast cell, allergy, genomic, biomarkers

Brief summary

Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which levels of functional activation in-vitro in primary cultured mast cells generated from the peripheral blood of single individuals can be assessed. It is the hypothesis that the test can be used to predict the potential state of in-vivo mast cell activation in any individual based on the functional activation profiles exhibited by their cultured mast cells. The investigators now wish to translate their in-vitro findings in a pilot study to disease groups where mast cell activation is expected to be high. These include highly allergic individuals; those with chronic idiopathic urticaria; those with mastocytosis; and those with the mast cell activation syndrome. Furthermore, they will use the functional genomics approach to identify gene expression biomarkers that are correlated with such diseases. The results will be compared with data that have been collected from a cohort of healthy control blood donors.

Detailed description

The objective of this study is to assess whether patients with severe allergic diseases exhibit high levels of mast cell activation as determined by the mast cell activation diagnostic test the investigators have developed. They anticipate that patients with history of severe allergic reactions will show up as high responders in the blood-based mast cell activation diagnostic test. Moreover, using microarray analysis as the approach for gene expression studies, they anticipate further that genomics biomarkers that are correlated with the high functional activation of the in-vitro mast cells derived from these patients can be readily identified. About 100 ml of peripheral venous blood from individual patients will be drawn into heparinized syringes and collected in a blood-collecting bag/tube containing silica. The bag/tube will be promptly processed for the generation of primary human mast cell cultures using the protocol that has previously been developed \[Inflammation Research 66: 25 (2017). After culturing for 9 weeks, the resulting human mast cells will be analyzed for both their functional activity in terms of histamine release in response to the activation of high-affinity Immunoglobulin E (IgE) receptors in these cells and their gene expression profiles using microarray analysis. The in-vitro functional and genomics data will be correlated with specific diagnoses and measurements of blood prostaglandin D2 (PGD2), PGD2 metabolites, tryptase and histamine levels in blood. For mediator assays, plasma from each subject will be collected after the cluster of differentiation 34 positive (CD34+) isolation step and the samples will be aliquoted and frozen at -80 degrees centigrade for subsequent analysis.

Interventions

None listed

Sponsors

Chinese University of Hong Kong
CollaboratorOTHER
Stanford University
CollaboratorOTHER
Hong Kong Sanatorium & Hospital
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Any patients with the above diagnoses -

Exclusion criteria

Children \< 18 years old; those who are unwilling or unable to donate blood; pregnant mothers. \-

Design outcomes

Primary

MeasureTime frameDescription
Mast Cell Activation Test Results for Validation GroupMast cells studied after 9 weeks in cultureMast Cell Activation Test results of high/low level of house dust mite sensitivity by using normal donor cultured mast cells for validation.
Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell ActivationMast cells studied after 9 weeks in culturePatient's serum was incubated with mast cells derived from normal donors for detection of mast cell activation as evidenced by histamine release.
Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess AutoreactivityMast cells studied after 9 weeks in culturepercentage of total histamine release by normal average responder mast cells that had been activated with patient's serum
Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgEMast cells studied after 9 weeks in culturepercentage of total histamine release by patient's mast cells that had been activated with anti-IgE
Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + AllergenMast cells studied after 9 weeks in culturePercentage of total histamine release when patient's mast cells were activated with patient's own serum and Der p2. Each patient's results are reported individually.
Cell Yield Per 100ml BloodMast cells studied after 9 weeks in cultureCell yield of patient's mast cell culture after 9 weeks in culture as an index of cell growth and differentiation.

Countries

Hong Kong

Participant flow

Recruitment details

19 patients were recruited in the study. 12 were used for validation. 7 were used for patient-specific testing. Therefore, there were 1 validation group and 7 individuals' result.

Participants by arm

ArmCount
Validation Group
Mast cell activation test employing normal donor cultured mast cells and allergic patient serum samples
12
SH#1
Male patient, Total IgE: 28918KU/L; Der p2IgE: 64.4KU/L; clinical diagnosis: Eczema
1
SH#2
Male patient, Total IgE: 22311KU/L; Der p2IgE: 91.24KU/L; clinical diagnosis: Eczema
1
SH#3
Female patient, Total IgE: 5333KU/L; Der p2IgE: \>100KU/L; clinical diagnosis: Eczema
1
SH#4
Male patient, Total IgE: 4070KU/L; Der p2IgE: \>100KU/L; clinical diagnosis: Eczema, Urticaria
1
SH#5
Male patient, Total IgE: 379KU/L; Der p2IgE: 0.15KU/L; clinical diagnosis: Exercise-induced anaphylaxis
1
SH#6
Female patient, Total IgE: 13KU/L; Der p2IgE: \<0.1KU/L; clinical diagnosis: Mast cell activation syndrome
1
SH#7
Male patient, Total IgE: 67KU/L; Der p2IgE: None KU/L; clinical diagnosis: Urticaria
1
Total19

Baseline characteristics

CharacteristicSH#7TotalSH#1SH#2SH#3SH#4SH#5SH#6Validation Group
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
1 Participants19 Participants1 Participants1 Participants1 Participants1 Participants1 Participants1 Participants12 Participants
Clinical diagnosis
Eczema
0 Participants7 Participants1 Participants1 Participants1 Participants0 Participants0 Participants0 Participants4 Participants
Clinical diagnosis
Eczema and Urticaria
0 Participants1 Participants0 Participants0 Participants0 Participants1 Participants0 Participants0 Participants0 Participants
Clinical diagnosis
Exercise-induced anaphylaxis
0 Participants1 Participants0 Participants0 Participants0 Participants0 Participants1 Participants0 Participants0 Participants
Clinical diagnosis
Mast cell activation syndrome
0 Participants1 Participants0 Participants0 Participants0 Participants0 Participants0 Participants1 Participants0 Participants
Clinical diagnosis
Rhinitis
0 Participants5 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants5 Participants
Clinical diagnosis
Urticaria
1 Participants4 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants3 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants18 Participants1 Participants1 Participants1 Participants1 Participants1 Participants0 Participants12 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants1 Participants0 Participants0 Participants0 Participants0 Participants0 Participants1 Participants0 Participants
Region of Enrollment
Hong Kong
1 participants7 participants1 participants1 participants1 participants1 participants1 participants1 participants12 participants
Sex: Female, Male
Female
0 Participants11 Participants0 Participants0 Participants1 Participants0 Participants0 Participants1 Participants9 Participants
Sex: Female, Male
Male
1 Participants8 Participants1 Participants1 Participants0 Participants1 Participants1 Participants0 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
deaths
Total, all-cause mortality
0 / 120 / 10 / 10 / 10 / 10 / 10 / 10 / 1
other
Total, other adverse events
0 / 120 / 10 / 10 / 10 / 10 / 10 / 10 / 1
serious
Total, serious adverse events
0 / 120 / 10 / 10 / 10 / 10 / 10 / 10 / 1

Outcome results

Primary

Cell Yield Per 100ml Blood

Cell yield of patient's mast cell culture after 9 weeks in culture as an index of cell growth and differentiation.

Time frame: Mast cells studied after 9 weeks in culture

Population: Mast cells derived from 7 allergic patients were analysed and reported individually. Patients in the validation group were not measured for this outcome and their samples were only used to validate the assay.

ArmMeasureValue (NUMBER)
Validation GroupCell Yield Per 100ml Blood14045000 Cell yield per 100ml blood
SH#1Cell Yield Per 100ml Blood2895522 Cell yield per 100ml blood
SH#2Cell Yield Per 100ml Blood115294 Cell yield per 100ml blood
SH#3Cell Yield Per 100ml Blood625263 Cell yield per 100ml blood
SH#4Cell Yield Per 100ml Blood4867778 Cell yield per 100ml blood
SH#5Cell Yield Per 100ml Blood352000 Cell yield per 100ml blood
SH#6Cell Yield Per 100ml Blood1400000 Cell yield per 100ml blood
Primary

Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation

Patient's serum was incubated with mast cells derived from normal donors for detection of mast cell activation as evidenced by histamine release.

Time frame: Mast cells studied after 9 weeks in culture

Population: Serum samples were obtained from 19 patients in total, of whom 12 were in the validation group. The other 7 patients were studied more extensively in the trial and their data is reported individually in this section and thereafter.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Validation GroupEvaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation0 Participants
SH#1Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation1 Participants
SH#2Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation0 Participants
SH#3Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation0 Participants
SH#4Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation0 Participants
SH#5Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation0 Participants
SH#6Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation0 Participants
SH#7Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation0 Participants
Primary

Mast Cell Activation Test Results for Validation Group

Mast Cell Activation Test results of high/low level of house dust mite sensitivity by using normal donor cultured mast cells for validation.

Time frame: Mast cells studied after 9 weeks in culture

Population: Mast cells were cultured from blood of normal donors to validate the (Mast Cell Activation) MAT assay. The serum samples were obtained from allergic patients with sensitivities to Der p2 and used for passive sensitization of normal donor mast cells followed by their activation by Der p2 allergen. Data were collected only from the validation group.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Validation GroupMast Cell Activation Test Results for Validation GroupHigh level of house dust mite sensitivityMAT positive6 Participants
Validation GroupMast Cell Activation Test Results for Validation GroupHigh level of house dust mite sensitivityMAT negative2 Participants
Validation GroupMast Cell Activation Test Results for Validation GroupLow level of house dust mite sensitivityMAT positive0 Participants
Validation GroupMast Cell Activation Test Results for Validation GroupLow level of house dust mite sensitivityMAT negative4 Participants
Primary

Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity

percentage of total histamine release by normal average responder mast cells that had been activated with patient's serum

Time frame: Mast cells studied after 9 weeks in culture

Population: Mast cells derived from the validation group is reported as a group (mean +/-SD). The other 7 allergic patients were analysed and reported individually as explained earlier.

ArmMeasureValue (MEAN)Dispersion
Validation GroupPercentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity2.15 percentage of histamine releasedStandard Deviation 0.71
SH#1Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity32.1 percentage of histamine released
SH#2Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity3.3 percentage of histamine released
SH#3Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity2.8 percentage of histamine released
SH#4Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity3.4 percentage of histamine released
SH#5Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity5.1 percentage of histamine released
SH#6Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity3.2 percentage of histamine released
SH#7Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity3.8 percentage of histamine released
Primary

Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE

percentage of total histamine release by patient's mast cells that had been activated with anti-IgE

Time frame: Mast cells studied after 9 weeks in culture

Population: Mast cells derived from 7 allergic patients were analysed and reported individually. Patients in the validation group were not measured for this outcome and their samples were only used to validate the assay.

ArmMeasureValue (NUMBER)
Validation GroupPercentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE11.5 percentage of histamine release
SH#1Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE38.3 percentage of histamine release
SH#2Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE69.6 percentage of histamine release
SH#3Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE47.9 percentage of histamine release
SH#4Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE36.3 percentage of histamine release
SH#5Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE45.5 percentage of histamine release
SH#6Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE41.6 percentage of histamine release
Primary

Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen

Percentage of total histamine release when patient's mast cells were activated with patient's own serum and Der p2. Each patient's results are reported individually.

Time frame: Mast cells studied after 9 weeks in culture

Population: Mast cells derived from 7 allergic patients were analysed and reported individually. Patients in the validation group were not measured for this outcome and their samples were only used to validate the assay.

ArmMeasureValue (NUMBER)
Validation GroupPercentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen24.5 percentage of histamine release
SH#1Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen54.7 percentage of histamine release
SH#2Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen79 percentage of histamine release
SH#3Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen8.4 percentage of histamine release
SH#4Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen0.2 percentage of histamine release
SH#5Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen0.2 percentage of histamine release
SH#6Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen0 percentage of histamine release

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026